NeuroScientific Biopharmaceuticals (ASX:NSB) has announced that it has commenced the transfer of its patented manufacturing process for its mesenchymal stromal cells from Cell and Tissue Therapy (Royal Perth Hospital) to Q-Gen Cell Therapeutics of QIMR Berghofer Medical Research Institute.

Amplia Therapeutics (ASX:ATX) has received Australian ethics approval for the Phase 2 clinical trial of narmafotinib in combination with the chemotherapy FOLFIRINOX.

Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the successful completion of a $203 million placement to institutional investors.

Prescient CEO James McDonnell said, “On behalf of the Board, I thank Prescient shareholders for their strong support of the SPP which allows us to accelerate the PTX-100 Phase 2 clinical plan. This is a pivotal moment for the business on its path towards our commercialisation objectives, and I am genuinely excited about the near-term milestones on this journey."

Alterity Therapeutics (ASX:ATH) has announced positive topline data from the ATH434-202 open-label Phase 2 clinical trial in people with multiple system atrophy.

Syntara Limited (ASX:SNT), a clinical-stage drug development company, has announced that the first participant has been dosed in the Phase 1a/b clinical trial for its topical pan-lysyl oxidase inhibitor SNT-9465, developed for the treatment of hypertrophic scars.

Radiopharm Theranostics (ASX: RAD) has announced that the US FDA has granted clearance of its Investigational New Drug application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody.

Sanofi has agreed to acquire Vicebio, a privately held biotechnology company headquartered in London, which has rights to the Molecular Clamp Technology developed at the University of Queensland.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at $439 million.

Amplia Therapeutics (ASX:ATX) has successfully undertaken an institutional placement of $25 million in new, fully paid ordinary shares in the company at a price of $0.23 per share.

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has completed patient recruitment for the TRIPP-FFX clinical trial.

Nyrada (ASX:NYR) has announced its intention to progress its candidate Xolatryp into a Phase 2a clinical trial for the treatment of acute myocardial infarction.

Percheron Therapeutics (ASX:PER) has shared new preclinical data for its investigational cancer drug, HMBD-002.

Australian-headquartered medical device company Atomo Diagnostics (ASX:AT1) has announced that it has placed the shortfall of $727,612.50 from the Share Purchase Plan with a range of sophisticated investors.

Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March.

Australian regenerative medicine company Osteopore (ASX:OSX) has secured clearance from the Research Governance Office at Princess Alexandra Hospital in Brisbane for its clinical trial for jawbone regeneration.

A study co-led by WEHI and the Peter Doherty Institute for Infection and Immunity has found that existing HIV drugs can suppress transmission of the HTLV-1 virus in mice.